Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Chiun-Sheng Huang

17PUBLICATIONS
187CO-AUTHORS
Molecular targetsPredictive and prognostic markersClinical midwiferyCancer therapy (excl. chemotherapy and radiation therapy)Ngā pūtaiao koiora-hauora, haumanu hoki o te Māori (Māori biomedical and clinical sciences)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

Sort by Publication Date:
|Jul 06, 2026
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management.

|Feb 21, 2026
The influence of immunohistochemistry-based subtypes on overall survival in breast cancer spine metastases: a systematic review and meta-analysis.

Fon-Yih Tsuang, Yun-Heng Li, Ting-Li Shen

|Jan 16, 2026
ctDNA Detected after Neoadjuvant Therapy for HER2-Positive Breast Cancer Is Associated with Inferior Outcomes and May Inform Adjuvant Therapy.

Po-Han Lin, Li-Wei Tsai, Chiao Lo

|Dec 10, 2025
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin

|Feb 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Peter A Fasching, Dennis Slamon, Zbigniew Nowecki

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

Pageof 3

Frequent Collaborators

3 joint publications

Miguel Martin

3 joint publications

Sibylle Loibl

3 joint publications

Nadia Harbeck

3 joint publications

Hope S Rugo

2 joint publications

Ching-Hung Lin

2 joint publications

Peter A Fasching

2 joint publications

Seock-Ah Im

2 joint publications

Carlos Barrios

2 joint publications

Zbigniew Nowecki

2 joint publications

Luca Gianni

Frequent Collaborators

3 joint publications

Miguel Martin

3 joint publications

Sibylle Loibl

3 joint publications

Nadia Harbeck

3 joint publications

Hope S Rugo